Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

• Cantourage brings “Craft” cannabis strain from the Canadian grower Plantations Cérès to the German medical market
• Plantations Cérès already the fourth “Craft” cannabis grower to supply Cantourage
• The cultivar “Slurricane Mint” is already being sold on the medical market in several Canadian provinces

Berlin, April 14, 2023 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01), a leading European company for the production and distribution of cannabis-based medicines, has announced its partnership with another “Craft” cannabis grower. Through the collaboration, Plantations Cérès is entering the European cannabis market for the first time with its “Slurricane Mint” strain and thus now also offering patients in this country additional therapeutic options.

With Plantations Cérès, Cantourage is adding a fourth “Craft” grower to its partner network, after Miracle Valley, Ostara Médical and LOT420, thus further expanding its range of “Craft” cannabis. This is in particularly high demand among patients due to its high quality. Cantourage has been supplying its “Craft” varieties to the medical market in the UK as well as Germany since December 2022.

Plantations Cérès is a family-run company based in St-Liguori, Québec. With more than 20 years of growing experience and with the help of state-of-the-art technologies, the growers are dedicated to the cultivation of high-quality “Craft” cannabis. The guiding principle here is quality over quantity. The focus on distributing small batches from controlled cultivation pays off in consistently high quality.

Philip Schetter, CEO of Cantourage, commented: “We are pleased to announce the cooperation with Plantations Cérès from Canada. We are convinced that the experience that our new cultivation partner brings as well as the quality of its products represent added value for the European market. The collaboration will allow us to further expand our range of high potency medicinal cannabis flowers to meet the growing demand for ‘Craft’ cannabis.”

Alexandre Lachapelle, founder of Plantations Cérès, said: “We built our production facility to the highest industry standards. One of our goals from the beginning was to also bring our strains to the European medical cannabis market. Thanks to our partnership with Cantourage, this is now possible. We are very grateful and happy that we can now help patients in Germany and Europe through our collaboration with Cantourage.”

About Cantourage
Cantourage is a leading European company for the production and distribution of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2018 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its "Fast Track Access" platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In doing so, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under the ticker symbol "HIGH".

More information: www.cantourage.com

This announcement does not constitute a public offer or an advertisement for a public offer in the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors in the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.
Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.

Press contact Cantourage:
Frederick Steudemann
M +49 (0)30 4701 350-50
pr@cantourage.com